Overview

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Status:
Recruiting

Trial end date:
2022-03-30

Target enrollment:

Participant gender:

Summary

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.

Phase:

Phase 2

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborators:

Celcuity, LLC
Genentech, Inc.

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel
Pertuzumab
Trastuzumab